Salveo Invests in PathogenDx – WSJ

Salveo is participating in the funding round with firms that include Altitude Investment Management, Panther Opportunity Fund, Canopy Ventures, Tendaji Investments, PB Venture Group, Halley Venture Partners and FlatIron Group, according to a spokesman for Salveo.

Read More
DT
Salveo Capital Announces Investment PathogenDx

With its cutting edge solutions and high quality products, PathogenDx represents an innovative and disruptive company that is changing the testing process for cannabis-related products as we know it,” said Jeffrey Howard, a Managing Partner at Salveo Capital. “We believe that as customers and growers continue to seek the

Read More
DT
How to Seize M&A Opportunities in Marijuana’s Gray Market

The conventional wisdom on Wall Street is that it’s impossible to time the market. Venture capitalists, however, know all too well that when investing in either startup companies or nascent industries, timing is everything. Nowhere is this more true, today, than in the emerging cannabis market.

Read More
DT
Salveo Capital Announces Investment in Flow Kana

“Flow Kana has quickly scaled its business in a relatively short time and is a perfect example of how the cannabis industry is evolving,” said Michael Gruber, a Managing Partner at Salveo Capital. “Flow Kana’s dedication and partnership with local farmers in Mendocino and Humboldt counties in California is

Read More
DT
Salveo Portfolio Company Front Range Raises $3MM For Expansion

Front Range Biosciences (“FRB” or the “Company”) a leading agricultural biotech company that specializes in tissue culture propagation of high value crops, is pleased to announce it has raised $3 million in bridge round funding. This funding will go towards scaling FRB’s processes, as well as expansion into California and other legal cannabis states in the United States

Read More
DT
Salveo Capital Executes First Closing, Completes Initial Investments

Salveo Capital is a private equity fund dedicated to supporting high growth businesses supporting the legal cannabis ecosystem, with a focus on companies across a few sectors: information, data & analytics; financial payments & services; medical products, formulations & delivery; ag-tech & grow systems; and business services.

Salveo has completed investments in Headset and Front Range Biosciences. Headset is a Washington state located firm providing key actionable analytics to manufacturers and retailers within the cannabis industry. Front Range is a biotechnology providing a cost effective method to produce disease-free clones.

Read More
DT
Salveo Capital Joins 16-Strong Cannabis Fund Market With Upgraded Team

“A lot of new initiatives are coming on. Before, we didn’t have states that were adding laws and awarding licenses, so there was a bit of a lag in the market that has started to change in about the last year,” explained Thiersch. “Now it is humming on all cylinders and we are seeing a ton of movement. There will be a lot of opportunity in the next one to two years especially if some of the big East Coast cities that are huge markets open up."

Read More
DT
Salveo Capital Re-launches Cannabis-Focused Salveo Fund I

The fund’s primary investment space will be in early stage ancillary businesses that enable the legal cannabis industry and that are not subject to state regulations. Key investment areas will include financial, payment, and banking businesses, grow systems, agriculture and operations, software, digital and IOT, genetics, chemistry, and business services.

Read More
DT
How Big Is The Market For Legal Pot!

Ready or not, with its legalization in several states and those old-school taboos surrounding weed being febrezed away, a massive dollar sign hangs above Marijuana industry as its potential growth projections outpace the smartphone industry.

Read More
DT
Institutional Investment Into Cannabis Is Inevitable

Up to this point financing of legal cannabis in the U.S. has relied largely on private money - friends and family raises, high net-worth individuals, and small to medium sized private investment firms. Banks and large investors have shied away from companies in the cannabis space, even for businesses that do not touch the plant. The federal prohibition on cannabis has led to this situation in which small investors and venture funds have become the industry’s financial backbone. This moment in time of individual investing power in cannabis is waning, however. As cannabis normalizes and as laws relax industry participation by institutional investors is inevitable. The only question is how prepared current cannabis stakeholders will be when it happens.

Read More
DT
The Most Effective Cannabis Legalization Strategy Is to Put Patients First

Yes, full personal use legalization would by definition give access to the widest range of patients, but it’s a reality that a large chunk of voters and legislators do not support fully legal cannabis. Step by step legalization, prioritizing medical access, has worked across the country at alleviating the suffering of countless people while also providing much needed education for skeptics. It’s important to push for what can pass, and then work from within that system to make people comfortable with more.

Read More
DT